Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated Enterococcus faecalis CECT7121
- Development stage
- Preclinical
- Lead developer
- Universidad Nacional del Centro de la Provincia de Buenos Aires
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intraperitoneal
01
Overview
Inactivated *Enterococcus faecalis* CECT7121 is a paraprobiotic (non-viable microbial cell) preparation derived from the probiotic strain *E. faecalis* CECT7121. It is primarily investigated for its immunomodulatory properties and its potential as an adjunct therapy to enhance the efficacy of antimicrobial agents. Preclinical research in murine models of *Salmonella Enteritidis* sepsis has demonstrated that the concomitant administration of this inactivated bacterium with fluoroquinolones, such as ciprofloxacin and enrofloxacin, significantly improves survival rates. The therapeutic effect is attributed to the stimulation of the host's innate immune response, which works synergistically with antibiotics to clear systemic infections and mitigate the development of antimicrobial resistance.
- Other names
- inactivated E. faecalis CECT7121heat-killed Enterococcus faecalis CECT7121
Beyond the preview
Go deeper on inactivated Enterococcus faecalis CECT7121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated Enterococcus faecalis CECT7121.